SUMMIT THERAPEUTICS INC.
SMMTLoading price...
Overview
Previous Close21.46
Open16.02
Ask16.16
Bid16.07
Day's Range15.14 - 16.81
52 Week Range13.83 - 30.98
PE Ratio(TTM)--
Market Cap12.51B
Volume18M
Avg. Volume3.21M
12 Months Earnings-921.62M
12 Months Revenue0.00
Profit/Loss
| PARTICULARS | TTM | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Operating Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 705.00k | 1.81M |
| Operating Expenses | 935.09M | 759.25M | 210.96M | 88.77M | 64.33M | 87.98M |
| Profit after Tax (Net Income) | -921.62M | -746.08M | -221.31M | -614.93M | -78.78M | -88.60M |
Company Profile
Sector: Healthcare
Industry: Biotechnology
HQ Location: Miami, United States
Website: https://www.smmttx.com
Co-CEO & Executive Chairman: Mr. Robert W. Duggan
Employees: 265
About Company:
Summit Therapeutics Inc., a biopharmaceutical company, focuses on discovery, development, and commercialization of patient, physician, caregiver, and societal friendly medicinal therapies. Its lead development candidate is ivonescimab, a bispecific antibody for immunotherapy through blockade of PD-1 with the anti-angiogenesis for the treatment of non-small lung cancer (NSCLC) and colorectal cancer (CRC). The company has also combined ivonescimab with chemotherapy, which is in phase III clinical trial for the patients with epidermal growth factor receptor, mutated, and locally advanced or metastatic non-squamous NSCLC; first-line metastatic NSCLC; and first-line unresectable metastatic CRC. It markets its products in the United states, Canada, Europe, Japan, Latin America, Middle East, and Africa. The company was founded in 2003 and is headquartered in Miami, Florida.